
Nuvectis Pharma, Inc. (NVCT) Market Cap
Nuvectis Pharma, Inc. has a market capitalization of $222.1M.
Financials based on reported quarter end 2025-12-31
Price: $8.38
โฒ 0.06 (0.66%)
Market Cap: 222.13M
NASDAQ ยท time unavailable
CEO: Ron Bentsur
Sector: Healthcare
Industry: Biotechnology
IPO Date: 2022-02-04
Website: https://www.nuvectis.com
Nuvectis Pharma, Inc. (NVCT) - Company Information
Market Cap: 222.13M ยท Sector: Healthcare
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Analyst Sentiment
Based on 2 ratings
Analyst 1Y Forecast: $10.00
Average target (based on 1 sources)
Consensus Price Target
Low
$10
Median
$10
High
$10
Average
$10
Potential Upside: 19.3%
Price & Moving Averages
Related Companies in Healthcare

AVIDITY BIOSCIENCES INC (RNA)
Healthcare
$0.22B
Mkt Cap

ORASURE TECHNOLOGIES INC (OSUR)
Healthcare
$0.22B
Mkt Cap

UTAH MEDICAL PRODUCTS INC (UTMD)
Healthcare
$0.22B
Mkt Cap

ANTERIS TECHNOLOGIES GLOBAL CORP (AVR)
Healthcare
$0.22B
Mkt Cap

ANIKA THERAPEUTICS INC (ANIK)
Healthcare
$0.23B
Mkt Cap

NEOGENOMICS INC (NEO)
Healthcare
$0.21B
Mkt Cap
Fundamentals Overview
๐ AI Financial Analysis
Powered by StockMarketInfo"NVCT reported minimal revenue of $0 and a net loss of $7.314M for the recent quarter. The company has faced substantial challenges, as evidenced by negative operating cash flow of $4.494M. With total assets of $31.709M, offset by total liabilities of $13.296M, NVCT maintains a healthy equity position of $18.413M and a net cash surplus, indicating strong financial backing. Despite these strengths, shareholder sentiment remains negative, reflected by a significant 18.96% decrease in share price over the past year. However, there was a notable 32.50% rebound in the past six months. The outlook remains uncertain with no dividend payments and ongoing operating losses, positioning NVCT as an entity that has yet to achieve revenue generation. The analyst consensus price target indicates stable expectations but lacks optimism given the current financial trajectory."
Revenue Growth
Company is pre-revenue.
Profitability
Negatively impacted with a net loss of $7.314M.
Cash Flow Quality
Negative operating cash flow of $4.494M.
Leverage & Balance Sheet
Strong equity position with net cash surplus.
Shareholder Returns
Price declined by 18.96% over the past year.
Analyst Sentiment & Valuation
Stable price targets suggest cautious optimism.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.